Iliac venous outflow obstruction has an important role in the expression of symptomatic chronic venous insufficiency. This anatomic obstruction is frequently overlooked, owing in part to diagnostic ...

Stenting of iliac artery disease in patients with severely calcified lesions or extensive peripheral artery disease (PAD)—who historically have been excluded from clinical trials—is safe and effective ...

VISIBILITY Iliac and DURABILITY Iliac Studies Evaluate the Safety and Effectiveness of Balloon Expandable and Self-Expanding Stents in Treating Iliac Artery Disease Each study is designed to evaluate ...

NATICK, Mass., Oct. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and ...

DUBLIN -- Medtronic plc today announced that its Protégé(TM) GPS(TM) self-expanding peripheral stent system has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . New data from the DURABILITY Iliac trial confirm the safety and effectiveness of primary stenting with two ...

Please provide your email address to receive an email when new articles are posted on . HOLLYWOOD, Fla. — Approved by the FDA in late January, the first balloon-expandable stent graft with an ...

The US Food and Drug Administration (FDA) has approved Abbott's Absolute Pro Vascular Self-Expanding Stent System for the treatment of iliac artery disease, a form of peripheral artery disease (PAD) ...

Background A 66-year-old man presented to hospital with gross hematuria and clots. He had previously undergone surgical repair of a right iliac artery aneurysm with placement of a vascular prosthesis ...

Advancing the treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced approval by the U.S. Food and Drug Administration (FDA) of the Assurant ® Cobalt Iliac ...

NATICK, Mass. and MIAMI, Jan. 16, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes for ...

The major obstacle for precise selection of patients for venous outflow stenting is the lack of a reliable test to measure a hemodynamically significant stenosis. The key for the physician is to be ...